BCL2L1 and neoplasm: The combination treatment of TG101348 and erlotinib obviously decreased the expressions of EGFR, p-EGFR, Bcl-xL and survivin, suppressed the activation of STAT3, induced apoptosis and inhibited tumor growth of EGFR-mutant NSCLC cells in vivo.